New Delhi: A major pharmaceutical company Sun Pharmaceutical Industries high single digits expected top line growth In the stream FiscalAccording to the Managing Director Dilip SanghviThe Mumbai-based firm reported a consolidated total revenue from operations of Rs 48,497 crore in FY24. The figure was Rs 43,886 crore in FY23.
“We expect high single-digit consolidated top line Development for fiscal 2025. All our businesses are poised for growth,” Sanghvi said in a call with analysts.
He said that in the current financial year pharmaceutical company I will be in Investment Phase for its many businesses.
“This includes, but is not limited to, the costs of product launches in the U.S. as our product portfolio grows.” Global Specialty Business “This trend is expected to continue,” Sanghvi said.
They said that R&D Investment This will account for 8-10 per cent of sales during the year.
Responding to a separate question, Sanghvi said, “We have to continue investing for the future. And our endeavour will be that when we are investing for the future, we do not do so at the cost of profitability.”
He added: “But even if it requires some more investment, we will do that because ultimately our focus is on building a business that is strong in the long term.”
As per the AIOCD AWACS MAT March 2024 report, sun pharma is ranked number one and holds a share of 8.5 percent market share Indian currency reserves exceed Rs 1,970 billion drug market,
The company reported a consolidated net profit of Rs 9,576 crore for the financial year ended March 31, 2024. It was Rs 8,474 crore in the financial year 2022-23.
sun-pharma-expects-high-single-digit-top-line-growth-in-current-fiscal-et-healthworld-pharma
